key: cord-0261760-s7vhr1wu authors: Racine-Brzostek, S. E.; Yee, J.; Sukhu, A.; Qiu, Y.; Rand, S.; Barron, P.; Hao, Y.; Yang, H. S.; Meng, Q. H.; Apple, F. S.; Shi, Y.; Chadburn, A.; Golden, E.; Formenti, S. C.; Cushing, M.; Zhao, Z. title: More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals date: 2021-08-05 journal: nan DOI: 10.1101/2021.08.04.21261561 sha: e2de0f109bbe0b07e8241b1ba9e7e774f4f47262 doc_id: 261760 cord_uid: s7vhr1wu Longitudinal studies are needed to evaluate the SARS-CoV-2 mRNA vaccine antibody response under real-world conditions. This longitudinal study investigated the quantity and quality of SARS-CoV-2 antibody response in 846 specimens from 350 subjects: comparing BNT162b2-vaccinated individuals (19 previously diagnosed with COVID-19 [RecoVax]; 49 never been diagnosed [NaiveVax]) to 122 hospitalized unvaccinated (HospNoVax) and 160 outpatient unvaccinated (OutPtNoVax) COVID-19 patients. NaiveVax experienced a delay in generating SARS-CoV-2 total antibody levels (TAb) and neutralizing antibodies (SNAb) after the 1st vaccine dose (D1), but a rapid increase in antibody levels was observed after the 2nd dose (D2). However, these never reached the robust levels observed in RecoVax. In fact, NaiveVax TAb and SNAb levels decreased 4-weeks post-D2 (p=0.003;p<0.001). For the most part, RecoVax TAb persisted throughout this study, after reaching maximal levels 2-weeks post-D2; but SNAb decreased significantly ~6-months post-D1 (p=0.002). Although NaiveVax avidity lagged behind that of RecoVax for most of the follow-up periods, NaiveVax did reach similar avidity by ~6-months post-D1. These data suggest that one vaccine dose elicits maximal antibody response in RecoVax and may be sufficient. Also, despite decreasing levels in TAb and SNAb overtime, long-term avidity maybe a measure worth evaluating and possibly correlating to vaccine efficacy. As the Coronavirus Disease 2019 (COVID-19) pandemic enters its second year with more than 3 193 million confirmed cases worldwide,(1) many countries look to effective prophylactic SARS-4 CoV-2 vaccines to help curb its spread and prevent the thousands of COVID-19 deaths reported 5 daily. (2) In December 2020, the United States Food and Drug Administration issued an 6 emergency use authorization (EUA) for two SARS-CoV-2 mRNA vaccines. Shortly thereafter, 7 New York State commenced their vaccination program by vaccinating healthcare workers. 8 9 In addition to clinical trials conducted to determine the safety and efficacy of the mRNA vaccines, (3) (4) (5) additional studies began describing the serological response to the vaccines 11 under "real-world" conditions, especially with the onset of the SARS-CoV-2 variants and case 12 reports of vaccine escape. (6) (7) (8) (9) (10) (11) (12) (13) Although the initial focus may be on overall antibody levels and 13 differences in the antibody response in previously seropositive versus seronegative vaccine 14 recipients, (6, 8, 11) other humoral antibody response factors need to be considered. Due to 15 their role in inactivating viruses and limiting the number of infected host cells, the presence of 16 neutralizing antibodies are often considered a gold standard in evaluating protective immune 17 responses. (14) Early studies describe differences in the neutralizing response post-vaccination 18 in those previously exposed versus naïve to SARS-CoV-2. (12, 15, 16) Binding avidity, the 19 intrinsic affinity of the antibody-antigen interaction, is another potential factor in evaluating the 20 quality of the antibody response. Studies show that overtime, the low avidity antibodies avidity, in 49 non-infected vaccinated (NaïveVax) and 19 previously infected vaccinated 1 (RecoVax) healthcare workers. The vaccine-induced response was then compared to the 2 natural post-infection antibody response in 160 non-vaccinated outpatients with mild COVID- 19 3 symptoms (OutPtNoVax) and 122 non-vaccinated COVID-19 hospitalized acutely infected 4 (HospNoVax) (20) during the early period of the pandemic. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261561 doi: medRxiv preprint 1 HospNoVax demographics are summarized in Table 1 OutPtNoVax: 160 adult patients who had presented to an outpatient clinic in person or via video visit and had been tested for suspicion of prior COVID-19 infection. Specimen for SARS-CoV-2 11 serology testing occurred during the time period 4/30/2020 -5/20/2020. As with the hospitalized 12 patients, antibodies generated by these patients would be most consistent with the initially 13 described SARS-CoV-2 virus. This outpatient cohort's demographics are summarized in Table 14 1. The median time from COVID-19 symptom onset to the outpatient visit was 47 days (IQR 43- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To complement the regression model, the TAb, neutralizing activity and avidity levels in all three 12 cohorts were analyzed by stratifying into three 2-week time periods: 0-13 days (0-2 weeks), 14- Of note, RecoVax consistently had higher TAb levels than NaïveVax, HospNoVax and 1A and 2A; Figure 4A ). The RecoVax TAb was substantially increased in the first two weeks 23 post-D1 with a median TAb of 882 RFU (IQR 93-9916) and continued to rise to a median TAb of 24 9916 (IQR 7455-9916; p=0.001)) during weeks 2-4. This remained stable during this 2 month 25 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 4C ). Its avidity slowly but consistently improved at a rate of 0.5x10 -11 6 /s per day. Its consistently stronger avidity was noted at multiple time points. For example, at 4- This is in stark contrast to NaïveVax's TAb, which had a more gradual increase in TAb levels, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The following conclusions can be drawn from our study. First, RecoVax individuals exhibited a (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. Similar concerns over poor antibody production and protection against SARS-CoV-2 have 21 arisen in at risk populations, such as those with hematological malignancies or transplant patients (38) (39) (40) . Although these at risk individuals mount a poorer quantitative antibody 23 response, it may be of interest to study their antibody avidity maturation profile and determine 24 whether it could offer any protection against the virus. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261561 doi: medRxiv preprint Limitations 1 Our study has several limitations. First, selection bias may exist in both the prospective and 2 retrospective studies. As the HospNoVax and OutPtNoVax specimen in the study were were older, with more severe symptoms and predominately male, (41) which was reflected in our All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. An additional 7 participants from the NYP-WELCOME study (47) were also included in the 10 prospective aspect of this study. Forty-three specimens had been collected from this cohort The TAb assay measures the overall interaction between SARS-CoV-2 antibodies and the RBD 20 of the virus spike (S) protein, with a read out of sample relative fluorescence unit (RFU). SNAb is a competitive binding assay, based on the anti-SARS-CoV-2 antibody-mediated 23 inhibition of the interaction between the ACE2 receptor protein and the RBD. The assay readout 24 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261561 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261561 doi: medRxiv preprint test was used for the comparison of three or more groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261561 doi: medRxiv preprint TAb (A) antibody response, SNAb (B) levels and avidity (C) after 4-6 weeks after vaccination or infection in RecoVax individuals (red circle), NaïveVax individuals (blue triangle), HospNoVax (green square) and OutPtNoVax (violet diamond). Horizontal black lines represent median values and whiskers represent 95% CI. Wilcoxon rank-sum was used for paired comparison while Kruskal-Wallis test was used for the comparison of three or more groups. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261561 doi: medRxiv preprint n/a n/a n/a DAOS to ED visit, days, Median, IQR n/a n/a 7 (4-10) n/a DAOS to outpatient visit, days, Median, IQR n/a n/a n/a 47 (43) (44) (45) (46) (47) (48) Test: W: Wilcoxon rank-sum test p = 0.2693; F: Fisher's exact test p=0.1231 DAOS: days after onset of symptoms An interactive web-based dashboard to track COVID-19 in real time WHO. Coronavirus Disease Dashboard Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2 Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 Vaccine Breakthrough Infections with SARS-CoV-2 Variants Human neutralizing antibodies elicited by SARS-CoV-2 infection Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 SARS-CoV-2 Antibody Response in Persons with Past Natural Infection TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability Evolution of antibody immunity to SARS-CoV-2 Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines (Basel) Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Testingon-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients COVID-19): situation report, 73. Geneva: World Health Organization The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication A correlate of protection for SARS-CoV-2 vaccines is urgently needed Evidence for antibody as a protective correlate for COVID-19 vaccines Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Strategies to guide the antibody affinity maturation process Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell Covid-19 vaccination in patients with multiple myeloma: Focus on immune response Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines (Basel) Clinical Characteristics of Covid-19 in New York City Association of Age With SARS-CoV-2 Antibody Response Age-and Sex-Associated Variations in the Sensitivity of Serological Tests Among Individuals Infected With SARS-CoV-2 Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. Vaccines (Basel) SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva Estimating regression models with unknown break-points